摘要
目的探讨基质金属蛋白酶-7(MMP-7)、基质金属蛋白酶-9(MMP-9)基因多态性与卵巢癌遗传易感性的关系。方法选择2018年2月至2020年12月在鄂东医疗集团黄石市中心医院接受治疗的90例卵巢癌患者作为卵巢癌组。选择同期在本院接受体检的90名女性健康体检者作为对照组。采用Snapshot技术进行MMP-7和MMP-9基因分型,分析MMP-7及MMP-9的基因多态性与卵巢癌风险、FIGO分期以及肿瘤分化程度的关系。结果卵巢癌组MMP-7的rs138970782位点以及MMP-9的rs3918255位点AA基因型比例、A等位基因比例均高于对照组(P均<0.05)。与FIGO分期Ⅰ~Ⅱ期相比,FIGO分期Ⅲ~Ⅳ期MMP-7的rs138970782位点以及MMP-9的rs3918255位点AA基因型比例、A等位基因比例均升高(P均<0.05)。低分化组MMP-7的rs138970782位点以及MMP-9的rs3918255位点AA基因型比例、A等位基因比例最高,其次为中分化组,高分化组最低(P均<0.05)。结论MMP-7和MMP-9的基因多态性与卵巢癌易感性、FIGO分期以及肿瘤分化程度均相关。
Objective To investigate the relationship between matrix metalloproteinase-7(MMP-7),matrix metalloproteinase-9(MMP-9)gene polymorphism and genetic susceptibility to ovarian cancer.Methods Ninety cases of ovarian cancer patients who received treatment in Department of Abdominal and Pelvic Floor and Oncology from February 2018 to December 2020 were selected as the ovarian cancer group.Ninety healthy subjects who received physical examination in our hospital during the same period were selected as the control group.Genotyping of MMP-7 and MMP-9 was performed using Snapshot technology.The relationship between MMP-7 and MMP-9 gene polymorphism and ovarian cancer risk,FIGO stage and tumor differentiation degree were analyzed.Results Compared with the control group,the proportion of AA genotype and A allele at rs138970782 of MMP-7 and rs3918255 of MMP-9 in ovarian cancer group were significantly increased(P all<0.05).Compared with FIGO stagingⅠ-Ⅱgroup,the proportion of AA genotype and A allele at rs138970782 of MMP-7 and rs3918255 of MMP-9 in FIGO stagingⅢ-Ⅳgroup were significantly increased(P all<0.05).The proportion of AA genotype and A allele at rs138970782 of MMP-7 and rs3918255 of MMP-9 in the low differentiation group was the highest,followed by the medium differentiation group and the lowest in the high differentiation group(P all<0.05).Conclusion The gene polymorphism of MMP-7 and MMP-9 is closely associated with the susceptibility to ovarian cancer,FIGO stage and tumor differentiation degree.
作者
胡鹏
朱小鹏
HU Peng;ZHU Xiaopeng(Department of Abdominal and Pelvic Floor and Oncology,Huangshi Central Hospital,Affiliated Hospital of Hubei Polytechnic University,Edong Healthcare Group,Huangshi 453000,China)
出处
《宁夏医科大学学报》
2022年第8期768-773,共6页
Journal of Ningxia Medical University
基金
湖北省卫健委联合基金项目(WJ2019H457)。